AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 62 min read$NTRA

Chapman Steven Leonard sold $1.5M of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 6,751 shares of Natera, Inc. (NTRA) at $226.15 ($1.53M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure details an open-market sale of 6,751 shares at $226.1472/share on June 4, with holdings after the trade and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Traders may treat this as a mild sentiment input rather than a fundamental catalyst due to the 10b5-1 structure.

03

What to watch

The article provides no context on total insider sales frequency, option exercises, or broader company news; without that, price reaction may be overstated.

Relevance 6/10Novelty 3/10Timing: After-hours/next-session read-through from the June 4 sale disclosed via Form 4 filed June 5.

Background

The article reports an SEC Form 4 insider transaction for Natera, Inc. (NTRA) by its CEO and President.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold 6,751 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any move would be more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine Form 4 disclosure with a stated pre-arranged 10b5-1 plan, providing less actionable information about near-term fundamentals.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated or sizable insider sales can reflect management’s risk management rather than bearish fundamentals—market may overreact.

Key entities

  • issuer
    Natera, Inc.

    Subject of the insider transaction disclosure (Form 4) involving CEO/President Chapman Steven Leonard.

  • insider
    Chapman Steven Leonard

    CEO and President who sold shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min
AUG 14
$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

fool.com6 min
AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min